JOHNSON & JOHNSON

JOHNSON & JOHNSON (JNJ) — Investment Memo

🐂 The Bull Case (Warren's voice)

JNJ is a high-margin toll booth collecting fees on the inevitable decay of the human body. We like companies where the customer doesn't have a choice, and in the case of specialized MedTech and life-saving pharmaceuticals, "price" is rarely the primary objection.

• The Pivot: By spinning off the consumer soap business (Kenvue), JNJ shed the baggage of low-margin litigation-prone commodities. They are now a pure-play, high-stakes innovator.
• Pricing Power: When a surgeon is using JNJ hardware or a patient is relying on an oncology drug, the economics are indifferent to inflation. They possess institutional stickiness—once they are in the hospital system, they stay there.
• The Demographics: The global population is aging; demand for these services is not a "nice-to-have," it is a structural certainty for the next three decades.
• Entry Strategy: This is a defensive fortress. We only step in when the market panics over regulatory noise or temporary patent cliffs, pushing the valuation well below the intrinsic value of its cash-generating potential.

🐻 The Bear Case (Charlie inverts)

Show me where I'll die, and I won't go there. JNJ is a company currently paying a high price to stand still, and the "Litigation Lottery" is a structural tax on shareholders.

• The R&D Black Hole: They are spending billions of dollars in R&D only to deliver flat Free Cash Flow ($19.7B in 2025 vs $16.1B in 2016). That is not compounding; that is running on a treadmill. When a company earns $94.2B in revenue but cannot grow its free cash flow, the "innovation" is just a cost-center, not a moat.
• The Litigation Abyss: You cannot evaluate the business without evaluating the liability. The talc powder fallout was not a one-time error; it was a symptom of a massive, sprawling corporate structure where liabilities are buried in subsidiaries.
• The Patent Cliff: Every drug is a ticking time bomb. The moment the patent expires, the margin collapses. They are forced to engage in expensive, desperate M&A (like Abiomed for $16.6B) just to replace the revenue they are about to lose. It is a high-stakes, perpetual game of Whac-A-Mole.

💰 Valuation & Margin of Safety

The DCF model produces an intrinsic value of $125.78 per share. The market is currently pricing JNJ for growth that the stagnating FCF figures simply do not support.

• Intrinsic value estimate: $125.78 per share
• 25% margin of safety entry: $94.34 per share (Conservative entry)
• 50% margin of safety entry: $62.89 per share (Buffett's "fat pitch" zone)

Verdict: The stock is currently expensive, as the market is paying for the name of the company rather than the flatlining cash flow reality. We will WATCH, but we have no interest at these levels given the capital intensity required just to keep revenue from decaying. We wait for the "litigation-induced panic" to bring the price down to our margin of safety.